1937.0000 1.40 (0.07%)
NSE Oct 10, 2025 09:49 AM
Volume: 44,713
 

1937.00
0.07%
HDFC Securities
Maintain BUY with a TP of Rs 1,035 (18x Jun-19E and Rs 135/sh for pipeline). Glenmarks (GNP) 1QFY18 performance was in stark contrast to that in the previous quarter. The overall top-line grew 23% YoY, largely on the back of ~50% growth in the US business (gZetia impact). Revenue was also surprisingly boosted by a 15% growth in the India business, despite the GST disruption in the domestic market. The EBITDA margin came in at 23.3%, in line with estimates, up 640bps YoY. PAT grew ~44% YoY to ~Rs 3.2bn.
Glenmark Pharmaceuti.. has an average target of 2144.00 from 5 brokers.
More from Glenmark Pharmaceuticals Ltd.
Recommended